Clinical Trial Update: A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study. [Phase 2]

View source ↗

Summary

A Phase II randomized trial is evaluating cemiplimab plus OSE2101 (TEDOPI) as maintenance therapy in ctDNA-positive non-small cell lung cancer and is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Libtayo (cemiplimab)
• Tedopi

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: NSCLC | Phase 2 | Status: RECRUITING